The FDA last week approved the...

...Takeda Pharmaceutical Company's Alunbrig as a first-line therapy for the treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, a rare form of the disease. But the drug will face hefty competition. Among the most advantaged therapies for the treatment of non-small cell lung cancer are Roche's Alecensa, which holds preferred status in the pharmacy benefit for 7% of covered lives, growing to 26% with prior authorization and/or step therapy, and Pfizer's Xalkori, which holds preferred status for 5% of covered lives (35% with PA/ST).

SOURCE: MMIT Analytics, as of 5/27/20